- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.10. | Genflow Biosciences PLC Announces Total Voting Rights | 164 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 31, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing... ► Artikel lesen | |
| 31.10. | Genflow Biosciences - Total Voting Rights | 2 | RNS | ||
| 24.10. | Genflow Biosciences PLC Announces Holding(s) in Company | 157 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / October 24, 2025 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen | |
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 22.10. | TRADING UPDATES: Genflow patent progress; Accsys new debt facilities | 1 | Alliance News | ||
| 22.10. | Genflow Biosciences announces second European patent application | 2 | Seeking Alpha | ||
| 22.10. | Genflow Biosciences PLC Announces Second European Patent Application | 187 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 22.10. | Genflow Biosciences - Second European Patent Application | 2 | RNS | ||
| 20.10. | Genflow Biosciences says European patent publication is "step forward" | 2 | Alliance News | ||
| 20.10. | Genflow Biosciences PLC Announces Recognition of Patentability of Claims | 143 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 20.10. | Genflow Biosciences - Recognition of Patentability of Claims | 2 | RNS | ||
| 10.10. | Genflow Biosciences hails data from trial of dog ageing gene therapy | 1 | Alliance News | ||
| 10.10. | Genflow Biosciences PLC Announces Update on Animal Health Program | 186 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 10.10. | Genflow Biosciences - Update on Animal Health Program | 1 | RNS | ||
| 09.10. | Genflow Biosciences PLC Announces Update, Equity Issue and PDMR Notification | 193 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 09.10. | Genflow Biosciences - Update, Equity Issue and PDMR Notification | 1 | RNS | ||
| 02.10. | Genflow Biosciences PLC Announces Issue of Equity | 306 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 02.10. | Genflow Biosciences - Issue of Equity - Correction | 2 | RNS | ||
| 02.10. | SMALL-CAP WINNERS & LOSERS: Argo Blockchain up; Genflow issues shares | 24 | Alliance News | ||
| 02.10. | Genflow Biosciences - Issue of Equity | 2 | RNS | ||
| 30.09. | Genflow Biosciences PLC Announces Half-Year Report | 390 | ACCESS Newswire | LONDON, UNITED KINGDOM / ACCESS Newswire / September 30, 2025 / Genflow (LSE:GENF)(OTCQB:GENFF) is pleased to announce its half year results for the six-month period ended 30 June 2025.Chairman's StatementIt... ► Artikel lesen |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 16,460 | +2,55 % | ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales | ||
| QIAGEN | 38,370 | +1,40 % | Märkte am Morgen: AMD, Uber, Super Micro Computer, Amgen, Qiagen | Nach dem starken Monatsauftakt hat der DAX spürbar an Schwung verloren. Der Leitindex fiel am Dienstag zeitweise um zwei Prozent, konnte sich aber leicht erholen und schloss 0,76 Prozent tiefer bei... ► Artikel lesen | |
| ARCELLX | 90,15 | -0,09 % | J&J, Legend withdraw ASH abstract assessing Carvykti against Gilead, Arcellx's rival CAR-T | ||
| COGENT BIOSCIENCES | 35,255 | +5,44 % | Aktien New York: Gewinne dank Signalen für Shutdown-Ende | NEW YORK (dpa-AFX) - An den US-Börsen knüpfen die Kurse am Montag mit einer Erholung an die späte Kursstabilisierung vom Freitag an. Wie schon zuvor in Asien und Europa hellten Anzeichen für eine mögliche... ► Artikel lesen | |
| BIONTECH | 96,50 | +2,82 % | Millionen für BioNTech und Evotec! Doch Medikamentenentwicklung kostet! Deshalb auf den Übernahmekandidaten NetraMark Aktie setzen!? | Nächste Erfolgsmeldung für NetraMark. Die KI des Unternehmens hat das nächste Biopharmaunternehmen überzeugt und wird immer mehr zum Übernahmekandidaten. Der neue Kunde will mit NetraAI seine klinische... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,82 | +0,17 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| EVOTEC | 5,380 | +5,37 % | DAX-Check LIVE: BMW, Auto1 Group, Evotec, Fresenius, Kontron, Siemens Healthineers, Vonovia | Nach dem freundlichen Auftakt in den Börsenmonat November geriet der DAX gestern deutlich unter Druck. Zwischenzeitlich rutschte der Leitindex im Tagestief um rund zwei Prozent ab. Auf dem niedrigeren... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 47,320 | +0,30 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 12,770 | +8,77 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering | ZUG, Switzerland, November 5, 2025 - MoonLake Immunotherapeutics (Nasdaq: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on advancing therapies to address significant unmet needs... ► Artikel lesen | |
| LENZ THERAPEUTICS | 25,540 | -3,44 % | LENZ Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| DYNE THERAPEUTICS | 18,610 | -5,44 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | - Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,820 | -1,88 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| MODERNA | 22,700 | +3,87 % | Moderna überrascht - Startschuss zur Trendwende? | Zugegeben: Die Erwartungen der Wall Street an den Quartalsbericht des Corona-Impfstoff-Entwicklers waren niedrig. Sehr niedrig. Dennoch konnte Moderna die Prognosen deutlich übertreffen. Die Aktie gewinnt... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 35,970 | +3,21 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)... ► Artikel lesen | |
| KEROS THERAPEUTICS | 17,470 | +3,34 % | Keros Therapeutics, Inc. - 10-Q, Quarterly Report |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,028 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.